Research programme: bispecific antibodies - Innovent Biologics

Drug Profile

Research programme: bispecific antibodies - Innovent Biologics

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Innovent Biologics
  • Class Bispecific antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 06 Jun 2016 Early research in Undefined indication in China (unspecified route)
  • 06 Jun 2016 Innovent Biologics in-licenses EpimAb's FIT-Ig® technology to develop and further license bispecific antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top